Most Recent
Pharmaceutical giant Lundbeck has resolved its battle with Novartis unit Sandoz over top-selling drug Lexapro, a battle that has raged for years and across multiple courts.
Swiss aircraft manufacturer Pilatus has won discovery to pursue a possible copyright claim stemming from a Royal Australian Air Force flight simulator contract.
Radio manufacturer Hytera wants the High Court to hear its appeal of a finding that it misappropriated Motorola's source code in a case of "substantial industrial theft”.
An appeals court has rejected Chinese radio manufacturer Hytera’s challenge to a finding it misappropriated the source code of US mobile phone giant Motorola.
Indian drug maker Cipla has lost a challenge to the extension of Novo Nordisk’s patent for Victoza, with a judge rejecting an argument that extensions can be granted only for active ingredients.
As it fends off a suit by AstraZeneca seeking to block the sale of a cheaper version of Brilinta, generics maker Pharmacor claims a patent for the heart attack drug should not have been extended.
Cipla is opposing the extension of Novo Nordisk’s patent for its Victoza weight loss and diabetes drug, arguing extensions can only be granted for active ingredients and not entire formulations.
AstraZeneca has brought court proceedings to block Australian drug maker Pharmacor from making a generic version of its heart attack drug Brilinta.
Novartis unit Sandoz is appealing a tribunal decision in favour of pharmaceutical company Lundbeck over a licence to sell a generic version of leading antidepressant Lexapro.
Banks targeted in long-running class actions over flexible commission schemes for car dealers are resisting the plaintiffs’ bid to amend their pleadings to “get around” the defence that certain claims are time-barred.